Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients

Androgen deprivation therapy (ADT) is first‐line palliative treatment in androgen receptor‐positive (AR+) salivary duct carcinoma (SDC), and response rates are 17.6–50.0%. We investigated potential primary ADT resistance mechanisms for their predictive value of clinical benefit from ADT in a cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: van Boxtel, Wim, Verhaegh, Gerald W., van Engen‐van Grunsven, Ilse A., van Strijp, Dianne, Kroeze, Leonie I., Ligtenberg, Marjolein J., van Zon, Hans B., Hendriksen, Yara, Keizer, Diederick, van de Stolpe, Anja, Schalken, Jack A., van Herpen, Carla M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187215/
https://www.ncbi.nlm.nih.gov/pubmed/31745978
http://dx.doi.org/10.1002/ijc.32795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187215/
https://www.ncbi.nlm.nih.gov/pubmed/31745978
http://dx.doi.org/10.1002/ijc.32795

Ejemplares similares